The Federation of Hellenic Enterprises (SEV) presented a series of proposals to reform pharmaceutical policy in the country. According to a SEV report, the reorganization and reform of health policy implemented during the years of crisis, have not heal structural inefficiencies in the health system.
According to data included in the report, in recent years, prescription and drug consumption remain stubbornly high, and rising (in Greece of 10.5 million. 6.5 million prescriptions were issued per month) and despite the fact that Greece, already before the crisis had a serious problem of over-consumption of pharmaceutical products.
Furthermore, national and international studies record in recent years trends of deterioration of important parameters related to the health care of the population, while a recent survey of Hellenic Statistical Authority recorded that a percentage of 12-14% of the population did not have access to necessary medical care or drugs needs and reduced visits to dentists in the period 2009-14.
The report notes further that “in all other countries, electronic prescriptions and even by active substance, has led to a reduction in public pharmaceutical expenditure and increasing the generic share, which are suitable for the most simple treatments, leaving innovative and more specialized drugs as a second line therapy where necessary. But in Greece, the disorderly, without internal consistency in the Greek reality and adaptation, implementation of international best practices, has led to a completely opposite result. ”
SEV proposes a series of measures including:
1. Information campaign about the harmful effects of over-consumption of drugs, but also the quality of generics.
2. Enhancing transparency at all levels, in terms of publicizing benefits offered by companies to doctors.
3. Total ban of selling antibiotics without a prescription.
4. Gross profit of pharmacists and distribution chain to increase proportionally if placing cheaper and especially generics drugs.
5. Reduction, proportionally, of the rebate of pharmacists in relation to the achievement of specific targets in the distribution of generics.
6. Implementation of clawback not on total market turnover, but in subcategories.
7. Interconnecting reduction of generic drug prices with market share growth.
8. Exemption from spending caps of clawback and rebate of special treatments, such as antiretroviral drugs and vaccines.
9. Allocation of most economic therapy as first-line, with the most expensive treatments to follow, where the first line of treatment did not result in a cure.
10. Utilization of the data obtained from electronic prescription, for identification of cases leading to a disproportionate increase in pharmaceutical expenditure.
11. Strengthening the National Organization for Medicines.
12. Accelerating the operation of the Health ministry’s Trading Commission.
13. Consistency in repaying state debts to enterprises.